Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05386563 · ClinicalTrials.gov registry record · NA
taVNS on Pupillary Response and Perceptual Learning
A NA study, sponsored by NYU Langone Health.
- Completed
- Registry status
- NA
- Development phase
- 12
- Enrollment target
NCT05386563: Completed NA study, sponsored by NYU Langone Health.
NCT05386563 is a NA study that has completed, run by NYU Langone Health. The registered enrollment target is 12 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05386563, a NA study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study has two parts. The study team will evaluate transcutaneous auricular vagal nerve stimulation (taVNS) and two sham settings during a passive task while measuring pupillary response. Second, the study team will assign either taVNS, sham, or no intervention during a go/no-go task and evaluate perceptual learning over three sessions which will also include measuring the pupillary response and electroencephalogram (EEG).
Primary Outcome
Will be measured during performance on a go/no-go task.
Interventions
- PROCEDURE Transcutaneous Auricular Vagal Nerve Stimulation (taVNS)
- PROCEDURE Sham Stimulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2022-05-18 |
| Est. Completion | 2025-07-09 |
| Phase | NA |
What the finished NCT05386563 record still lists
NCT05386563 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Transcutaneous Auricular Vagal Nerve Stimulation (taVNS) is the first listed.
NCT05386563 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05386563 about?
NCT05386563 is a clinical study titled "taVNS on Pupillary Response and Perceptual Learning". This study has two parts. The study team will evaluate transcutaneous auricular vagal nerve stimulation (taVNS) and two sham settings during a passive task while measuring pupillary response. Second, the study team will assign either taVNS, sham, or no intervention during a go/no-go task and evaluat...
What is the current status of trial NCT05386563?
This trial is currently completed. It is a NA study. The enrollment target is 12 participants. The study started on 2022-05-18. Estimated completion is 2025-07-09.
What interventions are being tested in trial NCT05386563?
The interventions under investigation include: Transcutaneous Auricular Vagal Nerve Stimulation (taVNS) (PROCEDURE), Sham Stimulation (PROCEDURE).
Who is sponsoring clinical trial NCT05386563?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05386563's enrollment target sits among peer trials
12 1913th of 2000 higher than 74 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI